Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PF-06936308 |
Synonyms | |
Therapy Description |
PF-06936308 is a replication defective serotype 68 chimpanzee adenovirus (AdC68) that expresses three undisclosed tumor associated antigens, potentially inducing a cytotoxic immune response against tumor cells expressing those antigens (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PF-06936308 | PF 06936308|PF 06936308 | PF-06936308 is a replication defective serotype 68 chimpanzee adenovirus (AdC68) that expresses three undisclosed tumor associated antigens, potentially inducing a cytotoxic immune response against tumor cells expressing those antigens (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03674827 | Phase I | PF-06936308 | A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC | Terminated | USA | 0 |